Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes

Metabolism: Clinical and Experimental

Volumn 48, Issue 9, 1999, Pages 1102-1107

  Kawai, Toshihide ^a   Takei, Izumi ^a   Oguma, Yuko ^a   Ohashi, Norimi ^a   Tokui, Mikiya ^a   Oguchi, Shuji ^a   Katsukawa, Fuminori ^a   Hirose, Hiroshi ^a   Shimada, Akira ^a   Watanabe, Kiyoaki ^a   Saruta, Takao ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; IMMUNOREACTIVE INSULIN; SOMATOMEDIN C; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ADULT; ARTICLE; BODY FAT; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIET THERAPY; HUMAN; HYPOTENSION; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS FAT; WEIGHT GAIN;

EID: 0000708629     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90122-1     Document Type: Article

References (44)

1. Olefsky JM: Pathogenesis of insulin resistance and hyperglycemia in non-insulin-dependent diabetes mellitus. Am J Med 79:1-7, 1985 (suppl 3B)
2. Horikoshi H, Fujiwara T, Yoshioka T, et al: Pharmacological characteristics of new anti-diabetic agent CS-045 in diabetic animals, in Shafrir E (ed): Frontiers in Diabetic Research, Lessons From Animal Diabetes 3. London, UK, Smith-Gordon, 1990, pp 320-324
3. Fujita T, Sugiyama Y, Taketomi S, et al: Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1 methylcyclohexylmethoxy) benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new anti-diabetic agent. Diabetes 32:804-810, 1983
4. Chang AY, Wyse BM, Gilchrist BJ, et al: Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocm-diabetic rats. Diabetes 32:830-838, 1983
5. Hosokawa T, Ando K, Tamura G: An ascochlorin derivative, AS-6, reduces insulin resistance in the genetically obese diabetic mouse, db/db. Diabetes 34:267-274, 1985
6. Fujiwara T, Yoshioka S, Yoshioka T, et al: Characterization of new oral anti-diabetic agent CS-045; studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988
7. Mimura K, Umeda F, Hiramatsu S, et al: Effects of a new oral hypoglycemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabet Med 11:685-691, 1994
8. Suter SL, Nolan JJ, Wallace P, et al: Metabolic effects of new oral hypoglycemic agent troglitazone in NIDDM subjects. Diabetes Care 15:193-203, 1992
9. Kuzuya T, Iwamoto Y, Kosaka K, et al: A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 11:147-154, 1991
10. Goodpaster BH, Thaete FL, Simoneau JA, et al: Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 46:1579-1585, 1997
11. Alessi MC, Pieretti F, Morange P, et al: Production of plasminogen activator 1 by human adipose tissue: Possible link between visceral fat and vascular disease. Diabetes 46:860-867, 1997
12. Jensen MD: Health consequences of fat distribution. Horm Res 48:88-92, 1997 (suppl 5)
13. Nakamura T, Kobayashi H, Yanagi K, et al: Importance of infra-abdominal visceral fat accumulation to coronary atherosclerosis in heterozygous familial hypercholesterolaemia. Int J Obes Relat Metab Disord 21:580-586, 1997
14. Sizer KM, Smith CL, Jacob CS, et al: Pioglitazone promotes insulin-induced activation of phosphoinositide 3-kinase in 3T3-L1 adipocytes, inhibiting a negative control mechanism. Mol Cell Endocrinol 102:119-129, 1994
15. Hirose H, Saito I, Kawai T, et al: Serum leptin level: Possible association with haematopoiesis in adolescents, independent of body mass index and serum insulin. Clin Sci 94:633-636, 1998
16. Tokunaga K, Matsuzawa Y, Ishikawa K, et al: A novel technique for determination of body fat by computed tomography. Int J Obes Relat Metab Disord 7:437-445, 1983
17. Yoshioka S, Nishino H, Shiraki T, et al: Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42:75-80, 1993
18. Kosaka K, Kuzuya T, Akanuma Y, et al: Clinical evaluation of a new oral hypoglycemic drug CS-045 in patients with non-insulin dependent diabetes mellitus poorly controlled by diet alone - A double blind, placebo controlled study. J Clin Ther Med 9:61-93, 1993 (suppl 3)
19. Ogihara T, Rakugi H, Ikegami H, et al: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 8:316-320, 1995
20. Björntorp P: The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord 20:291-302, 1996
21. Rosmond R, Lapidus L, Mårin P, et al: Mental distress, obesity and body fat distribution in middle-aged men. Obes Res 4:245-252, 1996
22. Ljung T, Andersson B, Bengtsson B-Å, et al: Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: A dose-response study. Obes Res 4:277-282, 1996
23. Rosmond R, Björntorp P: Endocrine and metabolic aberrations in men with abdominal obesity in relation to anxio-depressive infirmity. Metabolism 47:1187-1193, 1998
24. Rosmond R, Björntorp P: The interactions between hypothalamicpituitary-adrenal axis activity, testosterone, insulin-like growth factor 1 and abdominal obesity with metabolism and blood pressure in men. Int J Obes Relat Metab Disord 22:1184-1196, 1998
25. Seidell JC, Björntorp P, Sjöström L, et al: Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 39:897-901, 1990
26. Haffner SM, Valdez RA, Stern MP, et al: Obesity, body fat distribution and sex hormones in men. Int J Obes Relat Metab Disord 17:643-649, 1993
27. Brönnegård M, Arner P, Hellström L. et al: Glucocorticoid receptor messenger ribonucleic acid in different regions of human adipose tissue. Endocrinology 127:1689-1696, 1990
28. Després J-P: Body fat distribution, exercise and nutrition: Implications for prevention of atherogenic dyslipidemia, coronary heart disease, and non-insulin dependent diabetes mellitus, in Lamb DR, Murray R (eds): Perspectives in Exercise Science and Sports Medicine, Vol II. Exercise, Nutrition, and Weight Control. Carmel, IN, Cooper Publishing Group, 1998, pp 107-150
29. Ostman J, Arner P, Engfeldt P, et al: Regional differences in the control of lipolysis in human adipose tissue. Metabolism 28:1198-1205, 1979
30. Rebuffe-Scrive M, Andersson B, Olbe L, et al: Metabolism of adipose tissue in intraabdominal depots of nonobese men and women. Metabolism 38:453-458, 1989
31. Shimomura I, Tokunaga K, Kotani K, et al: Marked reduction of acyl-CoA synthetase activity and mRNA in intra-abdominal visceral fat by physical exercise. Am J Physiol 28:E44-E50, 1993
32. Mårin P, Rebuffé-Scrive M, Björntorp P: Uptake of triglyceride fatty acids in adipose tissue in vivo in man. J Clin Invest 6:131-137, 1990
33. Mårin P, Andersson B, Ottosson M: The morphology and metabolism of intra-abdominal adipose tissue in men. Metabolism 41:1242-1248, 1992
34. Mårin P, Odén B, Björntorp P: Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: Effects of androgens. J Clin Endocrinol Metab 80:239-243, 1995
35. Katsuki A, Sumida Y, Murashima S, et al: Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 83:859-862, 1998
36. Adams M, Montague CT, Prins JB, et al: Activators of peroxisome proliferator-activated receptor-gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100:3149-3153, 1997
37. Arner P: Differences in lipolysis between human subcutaneous and omental adipose tissue. Ann Med 27:435-438, 1995
38. Mårin P, Kvist H, Lindstedt G, et al: Low concentrations of insulin-like growth factor-1 in abdominal obesity. Int J Obes Relat Metab Disord 17:83-89, 1993
39. Nolan JJ, Olefsky JM, Nyce MR, et al: Effect of troglitazone on leptin production: Studies in vitro and in human subjects. Diabetes 45:1276-1278, 1996
40. Burant CF, Sreenan S, Hirano K, et al: Troglitazone action is independent on adipose tissue. J Clin Invest 100:2900-2908, 1997
41. Schwartz S, Raskin P, Fonseca V, et al: Effect of troglitazone in insulin-treated patients with type 2 diabetes mellitus. N Engl J Med 338:861-866, 1998
42. Zhang B. Berger J, Hu E, et al. Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. Mol Endocrinol 11:1457-1466, 1996
43. Spiegelman BM: PPAR-gamma; adipogemc regulator and thiazolidinedione receptor. Diabetes 47:507-514, 1998
44. Zhang B, Berger J, Zhou G, et al: Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J Biol Chem 271:31771-31774, 1996